Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-05-31
2011-05-31
Stockton, Laura L. (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C548S304700, C514S394000
Reexamination Certificate
active
07951956
ABSTRACT:
The present invention provides a benzimidazole compound represented by Formula (I)wherein X1is oxygen or carbonyl, and R1is a furan ring having 1 to 3 substituents or a pyrrole ring that may have 1 to 3 substituents; excluding compounds represented by Formula (I) wherein at least one of the substituents is a phosphoric acid group or a phosphoric ester group; or a salt thereof. The benzimidazole compound or salt thereof has excellent prostaglandin synthase inhibitory activity, and is useful as an agent for preventing and/or treating diseases in which prostaglandin D2 or metabolites thereof participates, such as allergic and inflammatory diseases, and as inhibitor for the exacerbation of Alzheimer's disease or cerebral damage.
REFERENCES:
patent: 1113808 (1968-05-01), None
patent: 2000-026430 (2000-01-01), None
patent: 2004-002248 (2004-01-01), None
patent: 2004-051600 (2004-02-01), None
patent: 2004-067629 (2004-03-01), None
patent: WO 98/39343 (1998-09-01), None
patent: WO 99/65886 (1999-12-01), None
patent: WO 02/076454 (2002-10-01), None
patent: WO 03/035065 (2003-05-01), None
patent: WO 2004/017963 (2004-03-01), None
patent: WO 2005/054232 (2005-06-01), None
patent: WO 2006/034418 (2006-03-01), None
Thompson et al., Current Medicinal Chemistry, Oct. 2002, 9(19), pp. 1751-1762.
Lee et al., Traceless solid-phase synthesis of 5-benzoylbenzimidazoles,Canadian Journal of Chemistry, 2001, vol. 79, No. 11, pp. 1556-1561, table 1.
Lewis et al., “Prostaglandin D2Generation After Activation of Rat and Human Mast Cells with Anti-IgE1”, The Journal of Immunology, vol. 129, No. 4, Oct. 1982, pp. 1627-1631.
Murray et al., “Release of Prostaglandin D2into Human Airways During Acute Antigen Challenge”, The New England Journal of Medicine, vol. 315, No. 13, Sep. 25, 1986, pp. 800-804.
Hardy et al., “The Bronchoconstrictor Effect of Inhaled Prostaglandin D2in Normal and Asthmatic Men”, The New England Journal of Medicine, vol. 311, Jul. 26, 1984, No. 4, pp. 209-213.
Nantel et al., “Expression of prostaglandin D synthase and the prostaglandin D2receptors DP and CRTH2 in human nasal mucosa”, Prostaglandins & Other Lipid Mediators, vol. 73 (2004), pp. 87-101.
Iwasaki et al., “Association of a New-Type Prostaglandin D2Receptor CRTH2 with Circulating T Helper 2 Cells in Patients with Atopic Dermatitis”, The Journal of Investigative Dermatology, vol. 119, No. 3 (2002), pp. 609-616.
Urade et al., “The Major Source of Endogenous Prostaglandin D2Production is Likely Antigen-Presenting Cells”, The Journal of Immunology, vol. 143, No. 9, Nov. 1, 1989, pp. 2982-2989.
Urade et al., “Mast Cells Contain Spleen-type Prostaglandin D Synthetase”, The Journal of Biological Chemistry, vol. 265, No. 1, Issue of Jan. 5, pp. 371-375, 1990.
Murakami et al., “c-Kit Ligand Mediates Increased Expression of Cytosolic Phospholipase A2, Prostaglandin Endoperoxide Synthase-1, . . . ”, The Journal of Biological Chemistry, vol. 270, No. 7, Issue of Feb. 17, pp. 3239-3246, 1995.
Fujitani et al., “Pronounced Eosinophilic Lung Inflammation and Th2 Cytokine Release in Human Lipocalin-Type Prostaglandin D Synthase Transgenic Mice”, The American Associate of Immunologists, vol. 168, pp. 443-449 (2002).
Matsuoka et al., “Prostaglandin D2as a Mediator of Allergic Asthma”, Science, vol. 287, Mar. 17, 2000, pp. 2013-2017.
Matsushita et al., “Pharmacological Studies on the Novel Antiallergic Drug HQL-79: I. Antiallergic and Antiasthmatic Effects in Various Experimental Models”, Jpn. J. Pharmacol, vol. 78, pp. 1-10, (1998).
Matsushita et al., “Pharmacological Studies on the Novel Antiallergic Drug HQL-79: II. Elucidation of Mechanisms for Antiallergic and Antiasthmatic Effects”, Jpn. J. Pharmacol. vol. 78, pp. 11-22, (1998).
Ito Yoshiki et al., “Allergic Diseases—Diagnosis and Treatment, Based on Guideline—Therapeutics for Allergic Diseases and Current Status . . . ”, Japanese Journal of Clinical and Experimental Medicine, 2001, vol. 79, No. 2, pp. 218-221 with abstract.
Tanaka Yoshiki
Togawa Michinori
Urade Yoshihiro
Yamane Keiko
Rothwell Figg Ernst & Manbeck P.C.
Stockton Laura L.
Taiho Pharmaceuticals Co., Ltd.
LandOfFree
Benzoimidazole compound capable of inhibiting prostaglandin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzoimidazole compound capable of inhibiting prostaglandin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzoimidazole compound capable of inhibiting prostaglandin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2681600